SG10201913085TA - Methods and compositions for treating a serpinc1-associated disorder - Google Patents
Methods and compositions for treating a serpinc1-associated disorderInfo
- Publication number
- SG10201913085TA SG10201913085TA SG10201913085TA SG10201913085TA SG10201913085TA SG 10201913085T A SG10201913085T A SG 10201913085TA SG 10201913085T A SG10201913085T A SG 10201913085TA SG 10201913085T A SG10201913085T A SG 10201913085TA SG 10201913085T A SG10201913085T A SG 10201913085TA
- Authority
- SG
- Singapore
- Prior art keywords
- serpinc1
- compositions
- treating
- methods
- associated disorder
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562264013P | 2015-12-07 | 2015-12-07 | |
US201662315228P | 2016-03-30 | 2016-03-30 | |
US201662366304P | 2016-07-25 | 2016-07-25 | |
US201662429241P | 2016-12-02 | 2016-12-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201913085TA true SG10201913085TA (en) | 2020-02-27 |
Family
ID=58800158
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913085TA SG10201913085TA (en) | 2015-12-07 | 2016-12-07 | Methods and compositions for treating a serpinc1-associated disorder |
SG11201804729RA SG11201804729RA (en) | 2015-12-07 | 2016-12-07 | Methods and compositions for treating a serpinc1-associated disorder |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201804729RA SG11201804729RA (en) | 2015-12-07 | 2016-12-07 | Methods and compositions for treating a serpinc1-associated disorder |
Country Status (15)
Country | Link |
---|---|
US (2) | US11091759B2 (pt) |
EP (1) | EP3386518A1 (pt) |
JP (3) | JP6985283B2 (pt) |
KR (3) | KR20180095843A (pt) |
CN (1) | CN108601795A (pt) |
AU (2) | AU2016368289C1 (pt) |
BR (1) | BR112018011450A2 (pt) |
CA (1) | CA3007014A1 (pt) |
CO (1) | CO2018006590A2 (pt) |
IL (2) | IL308717A (pt) |
MX (1) | MX2018006989A (pt) |
RU (2) | RU2021124592A (pt) |
SG (2) | SG10201913085TA (pt) |
TW (2) | TWI836281B (pt) |
WO (1) | WO2017100236A1 (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016069694A2 (en) | 2014-10-30 | 2016-05-06 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
TWI836281B (zh) | 2015-12-07 | 2024-03-21 | 美商健贊公司 | 治療serpinc1相關疾患之方法及組成物 |
US20200208150A1 (en) * | 2017-07-07 | 2020-07-02 | Alnylam Pharmaceuticals, Inc. | METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12) |
SG11201912243PA (en) * | 2017-07-10 | 2020-01-30 | Genzyme Corp | Methods and compositions for treating a bleeding event in a subject having hemophilia |
EP3550021A1 (en) * | 2018-04-05 | 2019-10-09 | Silence Therapeutics GmbH | Products and compositions for inhibiting expression of a target gene |
US20210155926A1 (en) * | 2018-04-05 | 2021-05-27 | Silence Therapeutics Gmbh | siRNAs WITH AT LEAST TWO LIGANDS AT DIFFERENT ENDS |
JP2022515744A (ja) * | 2018-12-20 | 2022-02-22 | プラクシス プレシジョン メディシンズ, インコーポレイテッド | Kcnt1関連障害の治療のための組成物及び方法 |
US20220079971A1 (en) * | 2019-01-16 | 2022-03-17 | Genzyme Corporation | SERPINC1 iRNA Compositions and Methods of Use Thereof |
MX2023000164A (es) | 2020-06-22 | 2023-07-06 | Genzyme Corp | Métodos y composiciones para tratar la hemofilia. |
WO2022120291A1 (en) | 2020-12-06 | 2022-06-09 | Genzyme Corporation | Treatment of hemophilia with fitusiran |
IL303452A (en) | 2020-12-06 | 2023-08-01 | Genzyme Corp | Treatment of hemophilia with Fitusiran |
WO2023118150A1 (en) | 2021-12-22 | 2023-06-29 | Royal College Of Surgeons In Ireland | A conjugate for use in localising a molecule to the vascular endothelium. |
TW202342065A (zh) | 2021-12-22 | 2023-11-01 | 美商健臻公司 | 治療血友病的方法和組成物 |
WO2023240193A2 (en) | 2022-06-08 | 2023-12-14 | Genzyme Corporation | Treatment of hemophilia with fitusiran in pediatric patients |
WO2023240199A2 (en) | 2022-06-08 | 2023-12-14 | Genzyme Corporation | Treatment of hemophilia with fitusiran |
WO2024094705A1 (en) | 2022-10-31 | 2024-05-10 | Sanofi | Drug delivery device having a two-part user indicator |
WO2024094703A1 (en) | 2022-10-31 | 2024-05-10 | Sanofi | Plunger for expelling a drug, drug delivery device, rear sub-assembly and corresponding methods |
WO2024094704A1 (en) | 2022-10-31 | 2024-05-10 | Sanofi | Arrangement for a drug delivery device, drug delivery device and method for assembly |
WO2024094701A1 (en) | 2022-10-31 | 2024-05-10 | Sanofi | Assembly for a drug delivery device |
WO2024094707A1 (en) | 2022-10-31 | 2024-05-10 | Sanofi | Drug delivery device with feedback element and method for providing a user of a drug delivery device feedback regarding a dose dispensing process |
WO2024094698A1 (en) | 2022-10-31 | 2024-05-10 | Sanofi | Front sub-assembly for a drug delivery device |
WO2024094706A1 (en) | 2022-10-31 | 2024-05-10 | Sanofi | Audible indicator, indicator holder and method of assembling an audible indicator |
WO2024094702A1 (en) | 2022-10-31 | 2024-05-10 | Sanofi | Device body for a drug delivery device, assembly for a drug delivery device and drug delivery device |
WO2024094699A1 (en) | 2022-10-31 | 2024-05-10 | Sanofi | Container holder and drug delivery device comprising the container holder |
WO2024094700A1 (en) | 2022-10-31 | 2024-05-10 | Sanofi | Method for assembling an assembly for a drug delivery device and drug delivery device. |
WO2024097190A1 (en) | 2022-11-02 | 2024-05-10 | Genzyme Corporation | Systems and methods for modeling thrombin-antithrombin |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4517294A (en) | 1982-03-03 | 1985-05-14 | Genentech, Inc. | Human antithrombin III |
US5783701A (en) | 1992-09-08 | 1998-07-21 | Vertex Pharmaceuticals, Incorporated | Sulfonamide inhibitors of aspartyl protease |
CA2592997A1 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Pseudo-adenovirus vectors |
CA2156288C (en) | 1993-02-19 | 2005-10-18 | Junichi Yano | Glycerol derivative, device and pharmaceutical composition |
US6191105B1 (en) | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
US6054299A (en) | 1994-04-29 | 2000-04-25 | Conrad; Charles A. | Stem-loop cloning vector and method |
WO2000022114A1 (en) | 1998-10-09 | 2000-04-20 | Ingene, Inc. | PRODUCTION OF ssDNA $i(IN VIVO) |
US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
US5994316A (en) | 1996-02-21 | 1999-11-30 | The Immune Response Corporation | Method of preparing polynucleotide-carrier complexes for delivery to cells |
JP4236812B2 (ja) | 1997-09-12 | 2009-03-11 | エクシコン エ/エス | オリゴヌクレオチド類似体 |
US6436989B1 (en) | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
IL136940A0 (en) | 1997-12-24 | 2001-06-14 | Vertex Pharma | Sulphonamide derivatives and pharmaceutical compositions containing the same |
WO2000022113A1 (en) | 1998-10-09 | 2000-04-20 | Ingene, Inc. | ENZYMATIC SYNTHESIS OF ssDNA |
TNSN00027A1 (fr) | 1999-02-12 | 2005-11-10 | Vertex Pharma | Inhibiteurs de l'aspartyle protease |
US6794493B2 (en) | 2000-04-07 | 2004-09-21 | Wisys Technology Foundation, Inc. | Antithrombin H-helix mutants |
IT1318539B1 (it) | 2000-05-26 | 2003-08-27 | Italfarmaco Spa | Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente |
WO2003015698A2 (en) | 2001-08-13 | 2003-02-27 | University Of Pittsburgh | Application of lipid vehicles and use for drug delivery |
EP1560931B1 (en) | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
JP5183064B2 (ja) | 2003-07-02 | 2013-04-17 | エムユーエスシー ファウンデイション フォー リサーチ デべロップメント | 甲殻類動物、及び他の無脊椎動物における、dsRNAで誘導された特異的、及び非特異的免疫、及びそこで使用する生物送達媒体 |
JP2005117918A (ja) | 2003-10-14 | 2005-05-12 | Glycomedics Inc | 新規糖鎖プライマー |
WO2005116204A1 (ja) | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Rna干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
CN101500548A (zh) | 2006-08-18 | 2009-08-05 | 弗·哈夫曼-拉罗切有限公司 | 用于体内递送多核苷酸的多缀合物 |
EP2066687A4 (en) | 2006-09-21 | 2010-12-08 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HAMP GENE |
US20100112687A1 (en) | 2007-03-02 | 2010-05-06 | Mdrna, Inc. | Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof |
JP2010533684A (ja) | 2007-07-20 | 2010-10-28 | ユニベルシテ パリ サッド 11 | 血液凝固異常の治療又は予防のための変異アンチトロンビンの使用 |
CA2910760C (en) | 2007-12-04 | 2019-07-09 | Muthiah Manoharan | Targeting lipids |
WO2009134487A2 (en) | 2008-01-31 | 2009-11-05 | Alnylam Pharmaceuticals, Inc. | Optimized methods for delivery of dsrna targeting the pcsk9 gene |
CA2717045C (en) | 2008-03-13 | 2018-04-10 | Celera Corporation | Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof |
CA2749772C (en) | 2009-01-16 | 2018-02-20 | Assistance Publique-Hopitaux De Paris | Mutated antithrombins, a process for preparing the same and their use as drugs |
US20120028816A1 (en) | 2009-03-31 | 2012-02-02 | Warren Stephen T | Methods and systems for screening for and diagnosing dna methylation associated with autism spectrum disorders |
EP2253715A1 (en) | 2009-05-14 | 2010-11-24 | RWTH Aachen | New targets for cancer therapy and/or diagnosis |
EA201791744A3 (ru) | 2009-06-10 | 2018-07-31 | Арбутус Биофарма Корпорэйшн | Улучшенная липидная композиция |
US9512164B2 (en) | 2009-07-07 | 2016-12-06 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide end caps |
EP3023495B1 (en) | 2010-02-24 | 2019-05-08 | Arrowhead Pharmaceuticals, Inc. | Compositions for targeted delivery of sirna |
CN112961855A (zh) | 2011-06-21 | 2021-06-15 | 阿尔尼拉姆医药品有限公司 | 血管生成素样3(ANGPTL3)iRNA组合物及其使用方法 |
US20140356377A1 (en) | 2011-08-25 | 2014-12-04 | Umc Utrecht Holding B.V. | Compounds for use in boosting coagulation |
EP2839006B1 (en) | 2012-04-20 | 2018-01-03 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
CN105408481B (zh) | 2013-05-22 | 2021-03-30 | 阿尔尼拉姆医药品有限公司 | SERPINA1 iRNA组合物及其使用方法 |
WO2015175510A1 (en) * | 2014-05-12 | 2015-11-19 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating a serpinc1-associated disorder |
US10689647B2 (en) | 2015-05-08 | 2020-06-23 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA |
TWI836281B (zh) | 2015-12-07 | 2024-03-21 | 美商健贊公司 | 治療serpinc1相關疾患之方法及組成物 |
-
2016
- 2016-12-07 TW TW110138147A patent/TWI836281B/zh active
- 2016-12-07 EP EP16822817.9A patent/EP3386518A1/en active Pending
- 2016-12-07 KR KR1020187019085A patent/KR20180095843A/ko not_active IP Right Cessation
- 2016-12-07 IL IL308717A patent/IL308717A/en unknown
- 2016-12-07 AU AU2016368289A patent/AU2016368289C1/en active Active
- 2016-12-07 WO PCT/US2016/065245 patent/WO2017100236A1/en active Application Filing
- 2016-12-07 RU RU2021124592A patent/RU2021124592A/ru unknown
- 2016-12-07 KR KR1020237025828A patent/KR20230119027A/ko not_active Application Discontinuation
- 2016-12-07 IL IL259795A patent/IL259795B2/en unknown
- 2016-12-07 US US15/371,300 patent/US11091759B2/en active Active
- 2016-12-07 SG SG10201913085TA patent/SG10201913085TA/en unknown
- 2016-12-07 CA CA3007014A patent/CA3007014A1/en active Pending
- 2016-12-07 SG SG11201804729RA patent/SG11201804729RA/en unknown
- 2016-12-07 JP JP2018549141A patent/JP6985283B2/ja active Active
- 2016-12-07 CN CN201680081199.2A patent/CN108601795A/zh active Pending
- 2016-12-07 BR BR112018011450A patent/BR112018011450A2/pt active Search and Examination
- 2016-12-07 MX MX2018006989A patent/MX2018006989A/es unknown
- 2016-12-07 TW TW105140410A patent/TWI743069B/zh active
- 2016-12-07 RU RU2018123712A patent/RU2754188C2/ru active
- 2016-12-07 KR KR1020217041486A patent/KR20210157474A/ko not_active IP Right Cessation
-
2018
- 2018-06-26 CO CONC2018/0006590A patent/CO2018006590A2/es unknown
-
2021
- 2021-07-14 US US17/375,785 patent/US20220017902A1/en active Pending
- 2021-11-24 JP JP2021189823A patent/JP7422120B2/ja active Active
-
2023
- 2023-02-14 AU AU2023200828A patent/AU2023200828A1/en active Pending
-
2024
- 2024-01-12 JP JP2024002987A patent/JP2024046760A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL259795A (en) | Methods and compositions for treating diseases associated with serpinc1 | |
HK1257295A1 (zh) | 用於免疫腫瘤學的組合物和方法 | |
HK1256602A1 (zh) | 用於治療翼狀胬肉的組合物和方法 | |
IL304820A (en) | Preparations and methods for the treatment of cancer | |
HK1248590A1 (zh) | 用於治療貧血的組合物和方法 | |
IL278004A (en) | Methods and preparations for treating conditions related to aging | |
PT3377516T (pt) | Composição para o tratamento do cancro | |
HK1244217A1 (zh) | 用於治療蛋白質病的方法 | |
HUE054673T2 (hu) | Rák kezelésére szolgáló eljárások és készítmények | |
IL256523A (en) | Compositions and methods for treating cancer | |
HK1251965A1 (zh) | 用於治療癲癇的方法 | |
EP3262065C0 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DYSTROGLYCANOPATHY DISEASES | |
IL255638A (en) | Compositions and methods for treating cancer | |
ZA201703771B (en) | Compositions and methods for treating hyperkalemia | |
HK1250958A1 (zh) | 用於治療癌症的組合物和方法 | |
HK1256371A1 (zh) | 用於治療腫瘤的方法 | |
GB201511447D0 (en) | Compositions and methods for treating biofilms | |
GB201511051D0 (en) | Compositions and methods for treating biofilms | |
GB201407949D0 (en) | Compositions and methods for treating biofilms |